JP3122400009 (JP3122400009)

$16.67T
Market Cap
64.5
P/E Ratio
0.86
Beta
0.21%
Dividend Yield
Piotroski 8/9Altman Z 31.8 SafeROIC−WACC +23.2%

Quantitative Summary

Deterministic

Financial health metrics are strong: Piotroski 8/9, Altman Z 31.8 (above 3.0 safe zone threshold).

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The company demonstrates exceptional fundamental quality, characterized by a robust ROIC-WACC spread of +23.2%, indicating highly efficient capital allocation that significantly outperforms the cost of equity. This efficiency is underpinned by superior profitability metrics, with net margins at 20.7% and gross margins expanding to 57.1%, suggesting strong pricing power or favorable product mix rather than reliance on leverage. The DuPont decomposition points clearly toward margin expansion as the primary driver of returns, given the high absolute levels of both top-line growth (60.3%) and bottom-line profitability. Furthermore, financial health is reinforced by a Piotroski F-Score of 8/9 and an Altman Z-Score of 31.8, signaling minimal distress risk and strong balance sheet stability relative to historical norms.

Valuation analysis reveals a significant divergence between current market pricing and intrinsic value estimates derived from discounted cash flow models. The stock trades at a premium multiple of 64.5x earnings, which is notably elevated when compared against typical sector benchmarks for mature companies, reflecting aggressive growth expectations embedded in the share price. However, this valuation appears disconnected from fundamental reality if one accepts the DCF fair value estimate of $12,329 per unit as a baseline; such a wide gap suggests the market may be overpricing future cash flows or assuming unsustainable continuation of the 60% revenue growth trajectory. The high P/E ratio implies that any deceleration in earnings could precipitate a sharp multiple contraction, making the current entry point sensitive to revisions in consensus guidance.

While specific risk factor deltas and insider activity data were not provided for this instrument, the combination of extreme valuation multiples and rapid top-line expansion inherently introduces volatility risks often associated with high-growth phases. The lack of sector classification limits cross-sectional comparison context, yet the standalone metrics suggest a business operating at an elite efficiency frontier that is currently priced as if it possesses permanent growth characteristics. Investors must weigh whether the implied perpetual growth rate within the DCF model justifies the 64.5x multiple or if the market has already discounted years of hyper-growth into today's price, leaving little room for error in execution.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →8.2%10.2%12.2%
2%$14945$11097$8779
3%$17380$12329$9498
4%$20984$13960$10394

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=10.2%, terminal growth 3%. Fair value $12329 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

8/9
Piotroski F-Score
Strong — high operational efficiency and profitability signals
31.8
Altman Z-Score
Safe Zone — above 3.0 threshold per academic model. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

57.1%
Gross Margin
20.7%
Net Margin
33.4%
ROIC
10.2%
WACC
ROIC − WACC Spread: +23.2%— Positive value creation spread.
+60.3%
Revenue Growth (YoY)
+158.8%
Earnings Growth (YoY)
266.5B
Free Cash Flow
10%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

Balance Sheet Health

0.69x
Debt / Equity
1.94x
Current Ratio
43.6x
Interest Coverage
-1.0x
Net Debt / EBITDA
1.62%
FCF Yield
257.1B
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $77.96
Act: $54.46
-30.1%
Q3
✓ Beat
Est: $94.31
Act: $123.14
+30.6%
Q2
✓ Beat
Est: $107.21
Act: $109.03
+1.7%
Q1
✓ Beat
Est: $76.73
Act: $108.41
+41.3%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

96.6
Forward P/E
PEG Ratio
24.73
Price/Book
10M
Avg Volume
$29345.00
52W High
$4703.00
52W Low
52W Range Position

Passive Flow Attribution

ETF Draft Effect
$1.7B
Tracked Passive Exposure
6
ETFs Holding JP3122400009
0.45%
Avg Weight in ETFs
$385B
Total ETF AUM

When investors buy or sell ETFs like EFA or IEFA, the fund manager is mechanically forced to buy or sell JP3122400009 shares regardless of JP3122400009's individual fundamentals. We estimate $1.7B of passive capital is structurally linked to JP3122400009 through 6 tracked ETFs. Index rebalances and ETF creation/redemption cycles can create noticeable volume spikes unrelated to company news.

Passive exposure = Σ (ETF AUM × stock weight in ETF) across 6 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.

ETF Contagion Visualizer

Simulate a price drop in JP3122400009 to visualize passive redemption contagion across ETFs and collateral stocks.

JP3122400009 Shock
-0%
Est. Passive Redemption
$0
Systemic Risk
STABLE
JP3122400009EpicenterIEFAETFEFAETFSCHFETFNL0010273215Low RiskCH0012032048Low RiskNVDALow RiskCH0012005267Low RiskAAPLLow Risk
JP3122400009 Price Drop (%)0

If JP3122400009 (JP3122400009) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ASML Holding N.V. (NL0010273215) as the most exposed collateral stock, sharing 3 ETFs with JP3122400009. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.

Contagion model based on shared ETF exposure and constituent weights across 6 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.

JP3122400009 Ownership Dynamics

Ticker
JP3122400009

Float lock-up computed from 6 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).

JP3122400009 Capital Efficiency

How efficiently does JP3122400009 convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$266.5B
EBITDA
$257.1B
FCF Conversion
104%
Reinvestment Rate
-4%
104% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
33.4%
ROIC − WACC Spread
23.2%

JP3122400009 converts 104% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 23.2% confirms that reinvested capital creates shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare JP3122400009 to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.